Literature DB >> 21723643

Nosocomial rotavirus gastroenteritis in a Canadian paediatric hospital: incidence, disease burden and patients affected.

P Verhagen1, D Moore, A Manges, C Quach.   

Abstract

Rotavirus is a well-recognised nosocomial pathogen in paediatric settings. Although rotavirus gastroenteritis is a vaccine-preventable disease, there is currently no publicly funded programme in Canada. The objective of this study was to inform rotavirus vaccination strategy by determining the incidence of nosocomial rotavirus gastroenteritis (NRVGE), estimating the burden of disease and characterising the patients affected. We performed a retrospective cohort study of all NRVGE cases over a period of 10 years in a Canadian tertiary-care paediatric hospital. Cases (N = 214) were identified by the hospital's prospective surveillance programme for nosocomial infections. The incidence was 0.5 per 1,000 patient-days (95% confidence interval: 0.43-0.57) with no significant decline over the 10-year period. The infection rate per hospital day was highest among patients with a hospital stay of > 5 days. A chronic underlying medical condition was present in 126 patients (59%), was often associated with previous hospitalisation, and was identifiable early in life for 95 patients (44%). Rehydration was required for 132 (62%) patients and was intravenous in 98 (46%). Twenty-six patients (12%) required readmission, for a median of four days, for NRVGE that occurred after discharge. Nosocomial rotavirus infection continues to be an important problem in paediatric hospitals, predominantly for children with underlying medical conditions requiring recurrent and prolonged hospitalisation. A rotavirus immunisation programme targeted at vulnerable patients, such as infants with congenital pathology and low birth weight, requires assessment in Canada and other countries that have not introduced universal rotavirus immunisation.
Copyright © 2011 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21723643     DOI: 10.1016/j.jhin.2011.04.020

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  4 in total

Review 1.  Do current cost-effectiveness analyses reflect the full value of childhood vaccination in Europe? A rotavirus case study.

Authors:  Bernd Brüggenjürgen; Mathie Lorrot; Fiona R Sheppard; Vanessa Rémy
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Group A rotaviruses in children with gastroenteritis in a Canadian pediatric hospital: The prevaccine era.

Authors:  Estelle Chetrit; Yvan L'homme; Jagdip Singh Sohal; Caroline Quach
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

3.  Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination.

Authors:  Patricia Bruijning-Verhagen; Marie-Josée J Mangen; Mariet Felderhof; Nico G Hartwig; Marlies van Houten; Léon Winkel; Wouter J de Waal; Marc J M Bonten
Journal:  BMC Med       Date:  2013-04-26       Impact factor: 8.775

4.  Acute Gastroenteritis Disease Burden in Infants With Medical Risk Conditions in the Netherlands.

Authors:  Josephine A P van Dongen; Elsbeth D M Rouers; Rob Schuurman; Marc J M Bonten; Patricia Bruijning-Verhagen
Journal:  Pediatr Infect Dis J       Date:  2021-04-01       Impact factor: 3.806

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.